Review



human osteosarcoma cell lines 143b  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    ATCC human osteosarcoma cell lines 143b
    Generation of organoids from sarcoma xenografts. (A) Representative images of organoids formed from tumor xenografts derived out of the indicated cell lines. (B) Organoids derived from the xenografts generated by parental (Par) and doxorubicin‐resistant (DXR) versions of the <t>143B</t> osteosarcoma cell line. Representative images of the cultures at Days 1, 2, and 5 are shown. (C) Histological analyses (hematoxylin and eosin staining) of xenograft and organoid samples of the indicated models. Aberrant mitoses (red arrowheads) and cells with osteoid‐like material in the cytoplasm (blue arrowheads) are indicated. Scale bars: 100 µm in (A) and (B), 50 µm in (C, left panels) and 30 µm in (C, right panels). (D and E) WES analysis of DNA samples ( n = 1) from cell line (CL) and organoid (O) cultures of 143B‐Par and 143B‐DXR models. (D) UpSet plot showing the intersections of genomic variants detected by WES in 143B‐Par and 143B‐DXR cell lines (CL) and their corresponding organoid (O) models. The inset shows a correlation plot with Jaccard indices for variant overlap between models. (E) Heatmap showing the VAFs of selected cancer‐related variants across all models.
    Human Osteosarcoma Cell Lines 143b, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1480 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+osteosarcoma+line/143B/pmc13744650-175-0-14
    Average 97 stars, based on 1480 article reviews
    human osteosarcoma cell lines 143b - by Bioz Stars, 2026-11
    97/100 stars

    Images

    1) Product Images from "Advancing in Sarcoma 3D Modeling: Identification of SRC as an Actionable Vulnerability in Doxorubicin‐Resistant Osteosarcoma Organoids"

    Article Title: Advancing in Sarcoma 3D Modeling: Identification of SRC as an Actionable Vulnerability in Doxorubicin‐Resistant Osteosarcoma Organoids

    Journal: MedComm

    doi: 10.1002/mco2.71134

    Generation of organoids from sarcoma xenografts. (A) Representative images of organoids formed from tumor xenografts derived out of the indicated cell lines. (B) Organoids derived from the xenografts generated by parental (Par) and doxorubicin‐resistant (DXR) versions of the 143B osteosarcoma cell line. Representative images of the cultures at Days 1, 2, and 5 are shown. (C) Histological analyses (hematoxylin and eosin staining) of xenograft and organoid samples of the indicated models. Aberrant mitoses (red arrowheads) and cells with osteoid‐like material in the cytoplasm (blue arrowheads) are indicated. Scale bars: 100 µm in (A) and (B), 50 µm in (C, left panels) and 30 µm in (C, right panels). (D and E) WES analysis of DNA samples ( n = 1) from cell line (CL) and organoid (O) cultures of 143B‐Par and 143B‐DXR models. (D) UpSet plot showing the intersections of genomic variants detected by WES in 143B‐Par and 143B‐DXR cell lines (CL) and their corresponding organoid (O) models. The inset shows a correlation plot with Jaccard indices for variant overlap between models. (E) Heatmap showing the VAFs of selected cancer‐related variants across all models.
    Figure Legend Snippet: Generation of organoids from sarcoma xenografts. (A) Representative images of organoids formed from tumor xenografts derived out of the indicated cell lines. (B) Organoids derived from the xenografts generated by parental (Par) and doxorubicin‐resistant (DXR) versions of the 143B osteosarcoma cell line. Representative images of the cultures at Days 1, 2, and 5 are shown. (C) Histological analyses (hematoxylin and eosin staining) of xenograft and organoid samples of the indicated models. Aberrant mitoses (red arrowheads) and cells with osteoid‐like material in the cytoplasm (blue arrowheads) are indicated. Scale bars: 100 µm in (A) and (B), 50 µm in (C, left panels) and 30 µm in (C, right panels). (D and E) WES analysis of DNA samples ( n = 1) from cell line (CL) and organoid (O) cultures of 143B‐Par and 143B‐DXR models. (D) UpSet plot showing the intersections of genomic variants detected by WES in 143B‐Par and 143B‐DXR cell lines (CL) and their corresponding organoid (O) models. The inset shows a correlation plot with Jaccard indices for variant overlap between models. (E) Heatmap showing the VAFs of selected cancer‐related variants across all models.

    Techniques Used: Organoids, Derivative Assay, Generated, H&E Stain, Xenograft Assay, Analysis, Variant Assay

    Response of parental and doxorubicin‐resistant organoids to antitumor drugs. Cell viability (CellTiter‐Glo 3D assays) measured after treatment of 143B‐Par (blue) and 143B‐DXR (red) organoids (solid line) and monolayer cultures (dotted line) with increasing concentrations of doxorubicin (DOX) (A), cisplatin (CIS) (B), methotrexate (MTX) (C), and mithramycin (MTM) (D) for 72 h. IC50 values (µM) obtained for each condition are shown. Error bars represent standard deviation of three independent biological replicates.
    Figure Legend Snippet: Response of parental and doxorubicin‐resistant organoids to antitumor drugs. Cell viability (CellTiter‐Glo 3D assays) measured after treatment of 143B‐Par (blue) and 143B‐DXR (red) organoids (solid line) and monolayer cultures (dotted line) with increasing concentrations of doxorubicin (DOX) (A), cisplatin (CIS) (B), methotrexate (MTX) (C), and mithramycin (MTM) (D) for 72 h. IC50 values (µM) obtained for each condition are shown. Error bars represent standard deviation of three independent biological replicates.

    Techniques Used: Organoids, Standard Deviation

    Transcriptomic characterization of the resistant phenotype in 143B‐DXR organoids. (A) Principal component analysis (PCA) of samples from three biological replicates of 143B‐Par (Par) and 143B‐DXR (DXR) organoids according to the top 500 most variable genes between conditions. (B) Volcano plot representing genes significantly upregulated (red) and downregulated (blue). A gene is considered differentially expressed if it has an FDR < 0.05 and a |log2FC| ≥ 1. The 10 most upregulated and downregulated genes are indicated. (C) Network representation of the statistical significance of the aggregate observed transcriptomic modulation of the gene and its interactors after applying LEAN. Only central nodes whose sub‐networks are composed of 50 nodes or more are represented. A scheme of the network including all significant nodes is shown in Figure . The color of the node indicates the log2FC from the differential expression analysis, while the color of the node border indicates corrected p value of the aggregate transcriptomic modulation according to LEAN. An unsupervised clustering of this network was performed, and the overrepresented pathway in each group is represented by the node shape. (D) Bar plot showing the top 20 hub nodes whose local networks contain a higher number of significant nodes according to LEAN. The bar color indicates the significance level for that node according to LEAN. (E) Representation of the local network centered on SRC, where node color indicates the log2FC and the border color represents the FDR from the differential expression analysis. Only the 50 most significant nodes are represented. A scheme of the SRC sub‐network including all significant nodes is shown in Figure .
    Figure Legend Snippet: Transcriptomic characterization of the resistant phenotype in 143B‐DXR organoids. (A) Principal component analysis (PCA) of samples from three biological replicates of 143B‐Par (Par) and 143B‐DXR (DXR) organoids according to the top 500 most variable genes between conditions. (B) Volcano plot representing genes significantly upregulated (red) and downregulated (blue). A gene is considered differentially expressed if it has an FDR < 0.05 and a |log2FC| ≥ 1. The 10 most upregulated and downregulated genes are indicated. (C) Network representation of the statistical significance of the aggregate observed transcriptomic modulation of the gene and its interactors after applying LEAN. Only central nodes whose sub‐networks are composed of 50 nodes or more are represented. A scheme of the network including all significant nodes is shown in Figure . The color of the node indicates the log2FC from the differential expression analysis, while the color of the node border indicates corrected p value of the aggregate transcriptomic modulation according to LEAN. An unsupervised clustering of this network was performed, and the overrepresented pathway in each group is represented by the node shape. (D) Bar plot showing the top 20 hub nodes whose local networks contain a higher number of significant nodes according to LEAN. The bar color indicates the significance level for that node according to LEAN. (E) Representation of the local network centered on SRC, where node color indicates the log2FC and the border color represents the FDR from the differential expression analysis. Only the 50 most significant nodes are represented. A scheme of the SRC sub‐network including all significant nodes is shown in Figure .

    Techniques Used: Organoids, Analysis, Quantitative Proteomics, Significance Assay

    SRC inhibition improves the response to doxorubicin in 143B‐DXR organoids through the suppression of cJUN–mediated ABCB1 expression. (A and B) Cell viability (CellTiterGlo‐3D assays) measured after treatment of 143B‐Par and/or 143B‐DXR organoids with DMSO (control) and the indicated concentrations of doxorubicin (DOX) alone or in combination with SRC inhibitors dasatinib (Dasa) (A) or saracatinib (Sara) (B) for 72 h. (C) Western blotting analyses of the indicated proteins in control conditions or after the treatment of 143B‐Par and 143B‐DXR organoids with 1 µM doxorubicin, 1 µM dasatinib, or the combination of both for 24 h. (D) Cell viability measured after treatment of 143B‐DXR organoids with DMSO (control) and the indicated concentrations of doxorubicin (DOX) alone or in combination with the JNK–IN‐8 for 72 h. (E) Western blotting analyses of the indicated proteins in control conditions or after the treatment of 143B‐DXR organoids with 1 µM Doxorubicin, 20 µM JNK–IN‐8, or the combination of both for 24 h. Error bars in panels A, B, and D represent standard deviation of three independent biological replicates and asterisks indicate statistically significant differences between doxorubicin monotherapy and combination treatments based on one‐way ANOVA tests. *: p < 0.05; **: p < 0.01; ***: p < 0.001. Other significant differences between the treatments shown in panels A, B, and D are depicted in Figure . Quantification of Western blotting analyses ( n = 1) are shown in Figures and .
    Figure Legend Snippet: SRC inhibition improves the response to doxorubicin in 143B‐DXR organoids through the suppression of cJUN–mediated ABCB1 expression. (A and B) Cell viability (CellTiterGlo‐3D assays) measured after treatment of 143B‐Par and/or 143B‐DXR organoids with DMSO (control) and the indicated concentrations of doxorubicin (DOX) alone or in combination with SRC inhibitors dasatinib (Dasa) (A) or saracatinib (Sara) (B) for 72 h. (C) Western blotting analyses of the indicated proteins in control conditions or after the treatment of 143B‐Par and 143B‐DXR organoids with 1 µM doxorubicin, 1 µM dasatinib, or the combination of both for 24 h. (D) Cell viability measured after treatment of 143B‐DXR organoids with DMSO (control) and the indicated concentrations of doxorubicin (DOX) alone or in combination with the JNK–IN‐8 for 72 h. (E) Western blotting analyses of the indicated proteins in control conditions or after the treatment of 143B‐DXR organoids with 1 µM Doxorubicin, 20 µM JNK–IN‐8, or the combination of both for 24 h. Error bars in panels A, B, and D represent standard deviation of three independent biological replicates and asterisks indicate statistically significant differences between doxorubicin monotherapy and combination treatments based on one‐way ANOVA tests. *: p < 0.05; **: p < 0.01; ***: p < 0.001. Other significant differences between the treatments shown in panels A, B, and D are depicted in Figure . Quantification of Western blotting analyses ( n = 1) are shown in Figures and .

    Techniques Used: Inhibition, Organoids, Expressing, Control, Western Blot, Standard Deviation

    In vivo antitumor effect of the doxorubicin–dasatinib combination. Xenografted mice generated from 143B‐DXR organoids were randomly assigned to the indicated treatment groups ( n = 7). (A) Curves representing the mean relative tumor volume of xenografts during treatment. Drug efficacy, expressed as the percentage of tumor growth inhibition (TGI), is indicated. (B) Changes in body weight during treatment. (C–F) Histological analysis of tumors collected at the end of treatment. (C) Representative images of hematoxylin and eosin (H&E) staining (top panels) and immunostaining for cJUN (middle panels) and ABCB1 (bottom panels). Necrotic areas (N) are indicated. Scale bars: 100 µm for H&E and 50 µm for cJUN and ABCB1. (D) Mean necrotic score. (E) Quantification of the percentage of cells showing different levels of cJUN staining intensity. (F) Mean ABCB1 score. Error bars represent SEM in panels A and B and SD in panels D–F. In panels A and B, data are from all mice ( n = 7 per group); in panel D, from tumors of all mice reaching the experimental endpoint ( n = 6 for control and dasatinib groups; n = 7 for doxorubicin and combination groups); and in panels E and F, from four randomly selected tumors per group. Asterisks indicate statistically significant differences between groups (* p < 0.05; ** p < 0.01). In panel E, the asterisk indicates significance for the high‐intensity group. Statistical analyses were performed using one‐way ANOVA followed by Tukey's multiple‐comparison test (D and F) or two‐way ANOVA followed by Tukey's multiple‐comparison test (A and E).
    Figure Legend Snippet: In vivo antitumor effect of the doxorubicin–dasatinib combination. Xenografted mice generated from 143B‐DXR organoids were randomly assigned to the indicated treatment groups ( n = 7). (A) Curves representing the mean relative tumor volume of xenografts during treatment. Drug efficacy, expressed as the percentage of tumor growth inhibition (TGI), is indicated. (B) Changes in body weight during treatment. (C–F) Histological analysis of tumors collected at the end of treatment. (C) Representative images of hematoxylin and eosin (H&E) staining (top panels) and immunostaining for cJUN (middle panels) and ABCB1 (bottom panels). Necrotic areas (N) are indicated. Scale bars: 100 µm for H&E and 50 µm for cJUN and ABCB1. (D) Mean necrotic score. (E) Quantification of the percentage of cells showing different levels of cJUN staining intensity. (F) Mean ABCB1 score. Error bars represent SEM in panels A and B and SD in panels D–F. In panels A and B, data are from all mice ( n = 7 per group); in panel D, from tumors of all mice reaching the experimental endpoint ( n = 6 for control and dasatinib groups; n = 7 for doxorubicin and combination groups); and in panels E and F, from four randomly selected tumors per group. Asterisks indicate statistically significant differences between groups (* p < 0.05; ** p < 0.01). In panel E, the asterisk indicates significance for the high‐intensity group. Statistical analyses were performed using one‐way ANOVA followed by Tukey's multiple‐comparison test (D and F) or two‐way ANOVA followed by Tukey's multiple‐comparison test (A and E).

    Techniques Used: In Vivo, Generated, Organoids, Inhibition, Analysis, Staining, Immunostaining, Control, Comparison

    Related Articles

    Mutagenesis:

    Article Title: Mitochondrial genotypes and radiation-induced micronucleus formation in human osteosarcoma cells in vitro.
    Article Snippet: We investigated whether or not the mitochondrial genotypes affect radiat ion-induced micronucleus (MN) formation.. For that purpose, the Q, KTl and Q° human osteosarcoma cell lines were used, which carry the wild-type mitochondrial DNA (mtDNA), the tRNA>' mutant mtDNA and no m t D N A , r e spec t i ve ly .. Desp i t e no s ignif icant difference in the clonogenic radiosensitivity, the g, KTl and Q° cel ls exh ib i t ed h igh , i n t e rmed ia t e and low rad iosensitivities, respectively, to the MN induction in cyto kinesis-blocked binucleated cells.



    Similar Products

    97
    ATCC human osteosarcoma cell lines 143b
    Generation of organoids from sarcoma xenografts. (A) Representative images of organoids formed from tumor xenografts derived out of the indicated cell lines. (B) Organoids derived from the xenografts generated by parental (Par) and doxorubicin‐resistant (DXR) versions of the <t>143B</t> osteosarcoma cell line. Representative images of the cultures at Days 1, 2, and 5 are shown. (C) Histological analyses (hematoxylin and eosin staining) of xenograft and organoid samples of the indicated models. Aberrant mitoses (red arrowheads) and cells with osteoid‐like material in the cytoplasm (blue arrowheads) are indicated. Scale bars: 100 µm in (A) and (B), 50 µm in (C, left panels) and 30 µm in (C, right panels). (D and E) WES analysis of DNA samples ( n = 1) from cell line (CL) and organoid (O) cultures of 143B‐Par and 143B‐DXR models. (D) UpSet plot showing the intersections of genomic variants detected by WES in 143B‐Par and 143B‐DXR cell lines (CL) and their corresponding organoid (O) models. The inset shows a correlation plot with Jaccard indices for variant overlap between models. (E) Heatmap showing the VAFs of selected cancer‐related variants across all models.
    Human Osteosarcoma Cell Lines 143b, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+osteosarcoma+line/143B/pmc13744650-175-0-14
    Average 97 stars, based on 1 article reviews
    human osteosarcoma cell lines 143b - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    97
    ATCC human osteosarcoma cell line 143b
    Generation of organoids from sarcoma xenografts. (A) Representative images of organoids formed from tumor xenografts derived out of the indicated cell lines. (B) Organoids derived from the xenografts generated by parental (Par) and doxorubicin‐resistant (DXR) versions of the <t>143B</t> osteosarcoma cell line. Representative images of the cultures at Days 1, 2, and 5 are shown. (C) Histological analyses (hematoxylin and eosin staining) of xenograft and organoid samples of the indicated models. Aberrant mitoses (red arrowheads) and cells with osteoid‐like material in the cytoplasm (blue arrowheads) are indicated. Scale bars: 100 µm in (A) and (B), 50 µm in (C, left panels) and 30 µm in (C, right panels). (D and E) WES analysis of DNA samples ( n = 1) from cell line (CL) and organoid (O) cultures of 143B‐Par and 143B‐DXR models. (D) UpSet plot showing the intersections of genomic variants detected by WES in 143B‐Par and 143B‐DXR cell lines (CL) and their corresponding organoid (O) models. The inset shows a correlation plot with Jaccard indices for variant overlap between models. (E) Heatmap showing the VAFs of selected cancer‐related variants across all models.
    Human Osteosarcoma Cell Line 143b, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+osteosarcoma+line/143B/pmc13756348-51-0-15
    Average 97 stars, based on 1 article reviews
    human osteosarcoma cell line 143b - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    98
    ATCC human osteoblast like osteosarcoma cell line
    Generation of organoids from sarcoma xenografts. (A) Representative images of organoids formed from tumor xenografts derived out of the indicated cell lines. (B) Organoids derived from the xenografts generated by parental (Par) and doxorubicin‐resistant (DXR) versions of the <t>143B</t> osteosarcoma cell line. Representative images of the cultures at Days 1, 2, and 5 are shown. (C) Histological analyses (hematoxylin and eosin staining) of xenograft and organoid samples of the indicated models. Aberrant mitoses (red arrowheads) and cells with osteoid‐like material in the cytoplasm (blue arrowheads) are indicated. Scale bars: 100 µm in (A) and (B), 50 µm in (C, left panels) and 30 µm in (C, right panels). (D and E) WES analysis of DNA samples ( n = 1) from cell line (CL) and organoid (O) cultures of 143B‐Par and 143B‐DXR models. (D) UpSet plot showing the intersections of genomic variants detected by WES in 143B‐Par and 143B‐DXR cell lines (CL) and their corresponding organoid (O) models. The inset shows a correlation plot with Jaccard indices for variant overlap between models. (E) Heatmap showing the VAFs of selected cancer‐related variants across all models.
    Human Osteoblast Like Osteosarcoma Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+osteosarcoma+line/MG-63/10__3390_slash_life16101733-74-0-7
    Average 98 stars, based on 1 article reviews
    human osteoblast like osteosarcoma cell line - by Bioz Stars, 2026-11
    98/100 stars
      Buy from Supplier

    99
    ATCC u2os human osteosarcoma cell lines
    Integrated single‐cell landscape of human <t>osteosarcoma.</t> (A) Harmony‐integrated UMAP of 39,063 quality‐controlled cells colored by global cluster. (B) The same embedding colored by patient, showing cross‐patient mixing after integration. (C) Reviewed major‐cell‐type annotations displayed on the integrated UMAP; labels mark lineage centroids. (D) Relative abundance of major cell types in each patient. Colors are consistent between panels C and D.
    U2os Human Osteosarcoma Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+osteosarcoma+line/U-2+OS/pmc13669654-131-2-11
    Average 99 stars, based on 1 article reviews
    u2os human osteosarcoma cell lines - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    97
    ATCC human osteosarcoma thymidine kinase deficient cell line 143b
    (a) Overview of the study including the development and validation of scMOCHA framework and large-scale discovery workflow for single-cell mtDNA variant analysis in human PBMC and BM samples. (b) Venn diagrams summarize the homoplasmic (purple), heteroplasmic (blue), and somatic (red) variants identified across PBMC and BM datasets. (c) Circos plots illustrate the genomic distribution and allele frequency (AF) of mtDNA variants across the mitochondrial genome in PBMC and BM. Tracks from outer to inner rings are: mitochondrial genome position (black), PhastCons100way conservation (yellow), population AF derived from gnomAD (black), sample frequency of homoplasmic variants (purple) and heteroplasmic variants (blue), the mitochondrial gene annotation map (middle), mean pseudobulk AF of homoplasmic variants (purple), heteroplasmic variants (blue), and somatic variants (red).
    Human Osteosarcoma Thymidine Kinase Deficient Cell Line 143b, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+osteosarcoma+line/143B/bio_rxiv__64898__2026__10__11__758340-271-1-10
    Average 97 stars, based on 1 article reviews
    human osteosarcoma thymidine kinase deficient cell line 143b - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    98
    ATCC human osteosarcoma cell lines saos 2
    (a) Overview of the study including the development and validation of scMOCHA framework and large-scale discovery workflow for single-cell mtDNA variant analysis in human PBMC and BM samples. (b) Venn diagrams summarize the homoplasmic (purple), heteroplasmic (blue), and somatic (red) variants identified across PBMC and BM datasets. (c) Circos plots illustrate the genomic distribution and allele frequency (AF) of mtDNA variants across the mitochondrial genome in PBMC and BM. Tracks from outer to inner rings are: mitochondrial genome position (black), PhastCons100way conservation (yellow), population AF derived from gnomAD (black), sample frequency of homoplasmic variants (purple) and heteroplasmic variants (blue), the mitochondrial gene annotation map (middle), mean pseudobulk AF of homoplasmic variants (purple), heteroplasmic variants (blue), and somatic variants (red).
    Human Osteosarcoma Cell Lines Saos 2, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+osteosarcoma+line/Saos-2/pm42826871-63-1-18
    Average 98 stars, based on 1 article reviews
    human osteosarcoma cell lines saos 2 - by Bioz Stars, 2026-11
    98/100 stars
      Buy from Supplier

    98
    ATCC human osteosarcoma cell line
    (a) Overview of the study including the development and validation of scMOCHA framework and large-scale discovery workflow for single-cell mtDNA variant analysis in human PBMC and BM samples. (b) Venn diagrams summarize the homoplasmic (purple), heteroplasmic (blue), and somatic (red) variants identified across PBMC and BM datasets. (c) Circos plots illustrate the genomic distribution and allele frequency (AF) of mtDNA variants across the mitochondrial genome in PBMC and BM. Tracks from outer to inner rings are: mitochondrial genome position (black), PhastCons100way conservation (yellow), population AF derived from gnomAD (black), sample frequency of homoplasmic variants (purple) and heteroplasmic variants (blue), the mitochondrial gene annotation map (middle), mean pseudobulk AF of homoplasmic variants (purple), heteroplasmic variants (blue), and somatic variants (red).
    Human Osteosarcoma Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+osteosarcoma+line/MG-63/10__2147_slash_ijn__s627313-80-2-9
    Average 98 stars, based on 1 article reviews
    human osteosarcoma cell line - by Bioz Stars, 2026-11
    98/100 stars
      Buy from Supplier

    99
    ATCC u2os human osteosarcoma cell line
    (a) Overview of the study including the development and validation of scMOCHA framework and large-scale discovery workflow for single-cell mtDNA variant analysis in human PBMC and BM samples. (b) Venn diagrams summarize the homoplasmic (purple), heteroplasmic (blue), and somatic (red) variants identified across PBMC and BM datasets. (c) Circos plots illustrate the genomic distribution and allele frequency (AF) of mtDNA variants across the mitochondrial genome in PBMC and BM. Tracks from outer to inner rings are: mitochondrial genome position (black), PhastCons100way conservation (yellow), population AF derived from gnomAD (black), sample frequency of homoplasmic variants (purple) and heteroplasmic variants (blue), the mitochondrial gene annotation map (middle), mean pseudobulk AF of homoplasmic variants (purple), heteroplasmic variants (blue), and somatic variants (red).
    U2os Human Osteosarcoma Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+osteosarcoma+line/U-2+OS/10__1038_slash_s41467___026___77989___w-300-10-15
    Average 99 stars, based on 1 article reviews
    u2os human osteosarcoma cell line - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    98
    ATCC culture human osteosarcoma cell lines
    (a) Overview of the study including the development and validation of scMOCHA framework and large-scale discovery workflow for single-cell mtDNA variant analysis in human PBMC and BM samples. (b) Venn diagrams summarize the homoplasmic (purple), heteroplasmic (blue), and somatic (red) variants identified across PBMC and BM datasets. (c) Circos plots illustrate the genomic distribution and allele frequency (AF) of mtDNA variants across the mitochondrial genome in PBMC and BM. Tracks from outer to inner rings are: mitochondrial genome position (black), PhastCons100way conservation (yellow), population AF derived from gnomAD (black), sample frequency of homoplasmic variants (purple) and heteroplasmic variants (blue), the mitochondrial gene annotation map (middle), mean pseudobulk AF of homoplasmic variants (purple), heteroplasmic variants (blue), and somatic variants (red).
    Culture Human Osteosarcoma Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+osteosarcoma+line/MG-63/10__1007_slash_s13402___026___01277___4-79-3-23
    Average 98 stars, based on 1 article reviews
    culture human osteosarcoma cell lines - by Bioz Stars, 2026-11
    98/100 stars
      Buy from Supplier

    Image Search Results


    Generation of organoids from sarcoma xenografts. (A) Representative images of organoids formed from tumor xenografts derived out of the indicated cell lines. (B) Organoids derived from the xenografts generated by parental (Par) and doxorubicin‐resistant (DXR) versions of the 143B osteosarcoma cell line. Representative images of the cultures at Days 1, 2, and 5 are shown. (C) Histological analyses (hematoxylin and eosin staining) of xenograft and organoid samples of the indicated models. Aberrant mitoses (red arrowheads) and cells with osteoid‐like material in the cytoplasm (blue arrowheads) are indicated. Scale bars: 100 µm in (A) and (B), 50 µm in (C, left panels) and 30 µm in (C, right panels). (D and E) WES analysis of DNA samples ( n = 1) from cell line (CL) and organoid (O) cultures of 143B‐Par and 143B‐DXR models. (D) UpSet plot showing the intersections of genomic variants detected by WES in 143B‐Par and 143B‐DXR cell lines (CL) and their corresponding organoid (O) models. The inset shows a correlation plot with Jaccard indices for variant overlap between models. (E) Heatmap showing the VAFs of selected cancer‐related variants across all models.

    Journal: MedComm

    Article Title: Advancing in Sarcoma 3D Modeling: Identification of SRC as an Actionable Vulnerability in Doxorubicin‐Resistant Osteosarcoma Organoids

    doi: 10.1002/mco2.71134

    Figure Lengend Snippet: Generation of organoids from sarcoma xenografts. (A) Representative images of organoids formed from tumor xenografts derived out of the indicated cell lines. (B) Organoids derived from the xenografts generated by parental (Par) and doxorubicin‐resistant (DXR) versions of the 143B osteosarcoma cell line. Representative images of the cultures at Days 1, 2, and 5 are shown. (C) Histological analyses (hematoxylin and eosin staining) of xenograft and organoid samples of the indicated models. Aberrant mitoses (red arrowheads) and cells with osteoid‐like material in the cytoplasm (blue arrowheads) are indicated. Scale bars: 100 µm in (A) and (B), 50 µm in (C, left panels) and 30 µm in (C, right panels). (D and E) WES analysis of DNA samples ( n = 1) from cell line (CL) and organoid (O) cultures of 143B‐Par and 143B‐DXR models. (D) UpSet plot showing the intersections of genomic variants detected by WES in 143B‐Par and 143B‐DXR cell lines (CL) and their corresponding organoid (O) models. The inset shows a correlation plot with Jaccard indices for variant overlap between models. (E) Heatmap showing the VAFs of selected cancer‐related variants across all models.

    Article Snippet: Human osteosarcoma cell lines 143B (CRL‐8303), SaOS‐2 (HTB‐85), and MG‐63 (CRL‐1427) were obtained from ATCC (Manassas, VA, USA).

    Techniques: Organoids, Derivative Assay, Generated, H&E Stain, Xenograft Assay, Analysis, Variant Assay

    Response of parental and doxorubicin‐resistant organoids to antitumor drugs. Cell viability (CellTiter‐Glo 3D assays) measured after treatment of 143B‐Par (blue) and 143B‐DXR (red) organoids (solid line) and monolayer cultures (dotted line) with increasing concentrations of doxorubicin (DOX) (A), cisplatin (CIS) (B), methotrexate (MTX) (C), and mithramycin (MTM) (D) for 72 h. IC50 values (µM) obtained for each condition are shown. Error bars represent standard deviation of three independent biological replicates.

    Journal: MedComm

    Article Title: Advancing in Sarcoma 3D Modeling: Identification of SRC as an Actionable Vulnerability in Doxorubicin‐Resistant Osteosarcoma Organoids

    doi: 10.1002/mco2.71134

    Figure Lengend Snippet: Response of parental and doxorubicin‐resistant organoids to antitumor drugs. Cell viability (CellTiter‐Glo 3D assays) measured after treatment of 143B‐Par (blue) and 143B‐DXR (red) organoids (solid line) and monolayer cultures (dotted line) with increasing concentrations of doxorubicin (DOX) (A), cisplatin (CIS) (B), methotrexate (MTX) (C), and mithramycin (MTM) (D) for 72 h. IC50 values (µM) obtained for each condition are shown. Error bars represent standard deviation of three independent biological replicates.

    Article Snippet: Human osteosarcoma cell lines 143B (CRL‐8303), SaOS‐2 (HTB‐85), and MG‐63 (CRL‐1427) were obtained from ATCC (Manassas, VA, USA).

    Techniques: Organoids, Standard Deviation

    Transcriptomic characterization of the resistant phenotype in 143B‐DXR organoids. (A) Principal component analysis (PCA) of samples from three biological replicates of 143B‐Par (Par) and 143B‐DXR (DXR) organoids according to the top 500 most variable genes between conditions. (B) Volcano plot representing genes significantly upregulated (red) and downregulated (blue). A gene is considered differentially expressed if it has an FDR < 0.05 and a |log2FC| ≥ 1. The 10 most upregulated and downregulated genes are indicated. (C) Network representation of the statistical significance of the aggregate observed transcriptomic modulation of the gene and its interactors after applying LEAN. Only central nodes whose sub‐networks are composed of 50 nodes or more are represented. A scheme of the network including all significant nodes is shown in Figure . The color of the node indicates the log2FC from the differential expression analysis, while the color of the node border indicates corrected p value of the aggregate transcriptomic modulation according to LEAN. An unsupervised clustering of this network was performed, and the overrepresented pathway in each group is represented by the node shape. (D) Bar plot showing the top 20 hub nodes whose local networks contain a higher number of significant nodes according to LEAN. The bar color indicates the significance level for that node according to LEAN. (E) Representation of the local network centered on SRC, where node color indicates the log2FC and the border color represents the FDR from the differential expression analysis. Only the 50 most significant nodes are represented. A scheme of the SRC sub‐network including all significant nodes is shown in Figure .

    Journal: MedComm

    Article Title: Advancing in Sarcoma 3D Modeling: Identification of SRC as an Actionable Vulnerability in Doxorubicin‐Resistant Osteosarcoma Organoids

    doi: 10.1002/mco2.71134

    Figure Lengend Snippet: Transcriptomic characterization of the resistant phenotype in 143B‐DXR organoids. (A) Principal component analysis (PCA) of samples from three biological replicates of 143B‐Par (Par) and 143B‐DXR (DXR) organoids according to the top 500 most variable genes between conditions. (B) Volcano plot representing genes significantly upregulated (red) and downregulated (blue). A gene is considered differentially expressed if it has an FDR < 0.05 and a |log2FC| ≥ 1. The 10 most upregulated and downregulated genes are indicated. (C) Network representation of the statistical significance of the aggregate observed transcriptomic modulation of the gene and its interactors after applying LEAN. Only central nodes whose sub‐networks are composed of 50 nodes or more are represented. A scheme of the network including all significant nodes is shown in Figure . The color of the node indicates the log2FC from the differential expression analysis, while the color of the node border indicates corrected p value of the aggregate transcriptomic modulation according to LEAN. An unsupervised clustering of this network was performed, and the overrepresented pathway in each group is represented by the node shape. (D) Bar plot showing the top 20 hub nodes whose local networks contain a higher number of significant nodes according to LEAN. The bar color indicates the significance level for that node according to LEAN. (E) Representation of the local network centered on SRC, where node color indicates the log2FC and the border color represents the FDR from the differential expression analysis. Only the 50 most significant nodes are represented. A scheme of the SRC sub‐network including all significant nodes is shown in Figure .

    Article Snippet: Human osteosarcoma cell lines 143B (CRL‐8303), SaOS‐2 (HTB‐85), and MG‐63 (CRL‐1427) were obtained from ATCC (Manassas, VA, USA).

    Techniques: Organoids, Analysis, Quantitative Proteomics, Significance Assay

    SRC inhibition improves the response to doxorubicin in 143B‐DXR organoids through the suppression of cJUN–mediated ABCB1 expression. (A and B) Cell viability (CellTiterGlo‐3D assays) measured after treatment of 143B‐Par and/or 143B‐DXR organoids with DMSO (control) and the indicated concentrations of doxorubicin (DOX) alone or in combination with SRC inhibitors dasatinib (Dasa) (A) or saracatinib (Sara) (B) for 72 h. (C) Western blotting analyses of the indicated proteins in control conditions or after the treatment of 143B‐Par and 143B‐DXR organoids with 1 µM doxorubicin, 1 µM dasatinib, or the combination of both for 24 h. (D) Cell viability measured after treatment of 143B‐DXR organoids with DMSO (control) and the indicated concentrations of doxorubicin (DOX) alone or in combination with the JNK–IN‐8 for 72 h. (E) Western blotting analyses of the indicated proteins in control conditions or after the treatment of 143B‐DXR organoids with 1 µM Doxorubicin, 20 µM JNK–IN‐8, or the combination of both for 24 h. Error bars in panels A, B, and D represent standard deviation of three independent biological replicates and asterisks indicate statistically significant differences between doxorubicin monotherapy and combination treatments based on one‐way ANOVA tests. *: p < 0.05; **: p < 0.01; ***: p < 0.001. Other significant differences between the treatments shown in panels A, B, and D are depicted in Figure . Quantification of Western blotting analyses ( n = 1) are shown in Figures and .

    Journal: MedComm

    Article Title: Advancing in Sarcoma 3D Modeling: Identification of SRC as an Actionable Vulnerability in Doxorubicin‐Resistant Osteosarcoma Organoids

    doi: 10.1002/mco2.71134

    Figure Lengend Snippet: SRC inhibition improves the response to doxorubicin in 143B‐DXR organoids through the suppression of cJUN–mediated ABCB1 expression. (A and B) Cell viability (CellTiterGlo‐3D assays) measured after treatment of 143B‐Par and/or 143B‐DXR organoids with DMSO (control) and the indicated concentrations of doxorubicin (DOX) alone or in combination with SRC inhibitors dasatinib (Dasa) (A) or saracatinib (Sara) (B) for 72 h. (C) Western blotting analyses of the indicated proteins in control conditions or after the treatment of 143B‐Par and 143B‐DXR organoids with 1 µM doxorubicin, 1 µM dasatinib, or the combination of both for 24 h. (D) Cell viability measured after treatment of 143B‐DXR organoids with DMSO (control) and the indicated concentrations of doxorubicin (DOX) alone or in combination with the JNK–IN‐8 for 72 h. (E) Western blotting analyses of the indicated proteins in control conditions or after the treatment of 143B‐DXR organoids with 1 µM Doxorubicin, 20 µM JNK–IN‐8, or the combination of both for 24 h. Error bars in panels A, B, and D represent standard deviation of three independent biological replicates and asterisks indicate statistically significant differences between doxorubicin monotherapy and combination treatments based on one‐way ANOVA tests. *: p < 0.05; **: p < 0.01; ***: p < 0.001. Other significant differences between the treatments shown in panels A, B, and D are depicted in Figure . Quantification of Western blotting analyses ( n = 1) are shown in Figures and .

    Article Snippet: Human osteosarcoma cell lines 143B (CRL‐8303), SaOS‐2 (HTB‐85), and MG‐63 (CRL‐1427) were obtained from ATCC (Manassas, VA, USA).

    Techniques: Inhibition, Organoids, Expressing, Control, Western Blot, Standard Deviation

    In vivo antitumor effect of the doxorubicin–dasatinib combination. Xenografted mice generated from 143B‐DXR organoids were randomly assigned to the indicated treatment groups ( n = 7). (A) Curves representing the mean relative tumor volume of xenografts during treatment. Drug efficacy, expressed as the percentage of tumor growth inhibition (TGI), is indicated. (B) Changes in body weight during treatment. (C–F) Histological analysis of tumors collected at the end of treatment. (C) Representative images of hematoxylin and eosin (H&E) staining (top panels) and immunostaining for cJUN (middle panels) and ABCB1 (bottom panels). Necrotic areas (N) are indicated. Scale bars: 100 µm for H&E and 50 µm for cJUN and ABCB1. (D) Mean necrotic score. (E) Quantification of the percentage of cells showing different levels of cJUN staining intensity. (F) Mean ABCB1 score. Error bars represent SEM in panels A and B and SD in panels D–F. In panels A and B, data are from all mice ( n = 7 per group); in panel D, from tumors of all mice reaching the experimental endpoint ( n = 6 for control and dasatinib groups; n = 7 for doxorubicin and combination groups); and in panels E and F, from four randomly selected tumors per group. Asterisks indicate statistically significant differences between groups (* p < 0.05; ** p < 0.01). In panel E, the asterisk indicates significance for the high‐intensity group. Statistical analyses were performed using one‐way ANOVA followed by Tukey's multiple‐comparison test (D and F) or two‐way ANOVA followed by Tukey's multiple‐comparison test (A and E).

    Journal: MedComm

    Article Title: Advancing in Sarcoma 3D Modeling: Identification of SRC as an Actionable Vulnerability in Doxorubicin‐Resistant Osteosarcoma Organoids

    doi: 10.1002/mco2.71134

    Figure Lengend Snippet: In vivo antitumor effect of the doxorubicin–dasatinib combination. Xenografted mice generated from 143B‐DXR organoids were randomly assigned to the indicated treatment groups ( n = 7). (A) Curves representing the mean relative tumor volume of xenografts during treatment. Drug efficacy, expressed as the percentage of tumor growth inhibition (TGI), is indicated. (B) Changes in body weight during treatment. (C–F) Histological analysis of tumors collected at the end of treatment. (C) Representative images of hematoxylin and eosin (H&E) staining (top panels) and immunostaining for cJUN (middle panels) and ABCB1 (bottom panels). Necrotic areas (N) are indicated. Scale bars: 100 µm for H&E and 50 µm for cJUN and ABCB1. (D) Mean necrotic score. (E) Quantification of the percentage of cells showing different levels of cJUN staining intensity. (F) Mean ABCB1 score. Error bars represent SEM in panels A and B and SD in panels D–F. In panels A and B, data are from all mice ( n = 7 per group); in panel D, from tumors of all mice reaching the experimental endpoint ( n = 6 for control and dasatinib groups; n = 7 for doxorubicin and combination groups); and in panels E and F, from four randomly selected tumors per group. Asterisks indicate statistically significant differences between groups (* p < 0.05; ** p < 0.01). In panel E, the asterisk indicates significance for the high‐intensity group. Statistical analyses were performed using one‐way ANOVA followed by Tukey's multiple‐comparison test (D and F) or two‐way ANOVA followed by Tukey's multiple‐comparison test (A and E).

    Article Snippet: Human osteosarcoma cell lines 143B (CRL‐8303), SaOS‐2 (HTB‐85), and MG‐63 (CRL‐1427) were obtained from ATCC (Manassas, VA, USA).

    Techniques: In Vivo, Generated, Organoids, Inhibition, Analysis, Staining, Immunostaining, Control, Comparison

    Integrated single‐cell landscape of human osteosarcoma. (A) Harmony‐integrated UMAP of 39,063 quality‐controlled cells colored by global cluster. (B) The same embedding colored by patient, showing cross‐patient mixing after integration. (C) Reviewed major‐cell‐type annotations displayed on the integrated UMAP; labels mark lineage centroids. (D) Relative abundance of major cell types in each patient. Colors are consistent between panels C and D.

    Journal: International Journal of Genomics

    Article Title: Integrative Single‐Cell and Bulk Transcriptomics Identifies a Proliferative Malignant State and Supports a Functional Contribution of TROAP in Osteosarcoma

    doi: 10.1155/ijog/1407947

    Figure Lengend Snippet: Integrated single‐cell landscape of human osteosarcoma. (A) Harmony‐integrated UMAP of 39,063 quality‐controlled cells colored by global cluster. (B) The same embedding colored by patient, showing cross‐patient mixing after integration. (C) Reviewed major‐cell‐type annotations displayed on the integrated UMAP; labels mark lineage centroids. (D) Relative abundance of major cell types in each patient. Colors are consistent between panels C and D.

    Article Snippet: HOS and U2OS human osteosarcoma cell lines were obtained from the American Type Culture Collection (ATCC; Manassas, Virginia, United States; HOS, CRL‐1543; U2OS, HTB‐96).

    Techniques: Single Cell

    TROAP depletion reduces clonogenic growth, overall wound closure, migration, and invasion in osteosarcoma cells. (A) Immunoblot analysis of TROAP in HOS and U2OS cells transfected with siNC, siTROAP‐1, or siTROAP‐2; beta‐actin is the loading control. (B) Colony‐formation images and colony counts. (C) Scratch‐wound images at 0 and 24 h and overall wound closure. Because the assay was not proliferation‐matched, it is not interpreted as direct migration evidence. (D) Transwell migration and invasion images and cell counts. Data are mean + /−standard deviation from three independent biological experiments. One‐way ANOVA with Dunnett′s test compared each siTROAP group with siNC; ∗∗∗ p < 0.001.

    Journal: International Journal of Genomics

    Article Title: Integrative Single‐Cell and Bulk Transcriptomics Identifies a Proliferative Malignant State and Supports a Functional Contribution of TROAP in Osteosarcoma

    doi: 10.1155/ijog/1407947

    Figure Lengend Snippet: TROAP depletion reduces clonogenic growth, overall wound closure, migration, and invasion in osteosarcoma cells. (A) Immunoblot analysis of TROAP in HOS and U2OS cells transfected with siNC, siTROAP‐1, or siTROAP‐2; beta‐actin is the loading control. (B) Colony‐formation images and colony counts. (C) Scratch‐wound images at 0 and 24 h and overall wound closure. Because the assay was not proliferation‐matched, it is not interpreted as direct migration evidence. (D) Transwell migration and invasion images and cell counts. Data are mean + /−standard deviation from three independent biological experiments. One‐way ANOVA with Dunnett′s test compared each siTROAP group with siNC; ∗∗∗ p < 0.001.

    Article Snippet: HOS and U2OS human osteosarcoma cell lines were obtained from the American Type Culture Collection (ATCC; Manassas, Virginia, United States; HOS, CRL‐1543; U2OS, HTB‐96).

    Techniques: Migration, Western Blot, Analysis, Transfection, Control, Colony Assay, Standard Deviation

    (a) Overview of the study including the development and validation of scMOCHA framework and large-scale discovery workflow for single-cell mtDNA variant analysis in human PBMC and BM samples. (b) Venn diagrams summarize the homoplasmic (purple), heteroplasmic (blue), and somatic (red) variants identified across PBMC and BM datasets. (c) Circos plots illustrate the genomic distribution and allele frequency (AF) of mtDNA variants across the mitochondrial genome in PBMC and BM. Tracks from outer to inner rings are: mitochondrial genome position (black), PhastCons100way conservation (yellow), population AF derived from gnomAD (black), sample frequency of homoplasmic variants (purple) and heteroplasmic variants (blue), the mitochondrial gene annotation map (middle), mean pseudobulk AF of homoplasmic variants (purple), heteroplasmic variants (blue), and somatic variants (red).

    Journal: bioRxiv

    Article Title: Single-cell variant landscape of the human mitochondrial genome reveals cell type-specific functions and disease mechanisms

    doi: 10.64898/2026.10.11.758340

    Figure Lengend Snippet: (a) Overview of the study including the development and validation of scMOCHA framework and large-scale discovery workflow for single-cell mtDNA variant analysis in human PBMC and BM samples. (b) Venn diagrams summarize the homoplasmic (purple), heteroplasmic (blue), and somatic (red) variants identified across PBMC and BM datasets. (c) Circos plots illustrate the genomic distribution and allele frequency (AF) of mtDNA variants across the mitochondrial genome in PBMC and BM. Tracks from outer to inner rings are: mitochondrial genome position (black), PhastCons100way conservation (yellow), population AF derived from gnomAD (black), sample frequency of homoplasmic variants (purple) and heteroplasmic variants (blue), the mitochondrial gene annotation map (middle), mean pseudobulk AF of homoplasmic variants (purple), heteroplasmic variants (blue), and somatic variants (red).

    Article Snippet: The human osteosarcoma thymidine kinase-deficient cell line 143B(TK − ) (ATCC CRL-8303) and human embryonic kidney HEK293 cells were maintained in Dulbecco’s Modified Eagle Medium GlutaMAX (DMEM; Thermo Fisher Scientific, 10569044) containing high glucose (4.5 g/L) and sodium pyruvate (110 mg/L), supplemented with 1% non-essential amino acids (NEAA) and 10% fetal bovine serum (FBS).

    Techniques: Biomarker Discovery, Single Cell, Variant Assay, Analysis, Derivative Assay